Mengesha Bethlehem, Asenov Asen G, Hirsh-Raccah Bruria, Amir Offer, Pappo Orit, Asleh Rabea
Heart Institute, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel.
Division of Clinical Pharmacology, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel.
Vaccines (Basel). 2022 Apr 8;10(4):575. doi: 10.3390/vaccines10040575.
Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on historical data according to a large national study in Israel. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose, and the presentation is usually mild. Recently, the third (booster) dose has been shown to reduce confirmed infections and severe illness even against common variants of the virus. In Israel, over 4.4 million citizens (more than 45% of the population) have been vaccinated with the third dose of Pfizer-BioNTech vaccine BNT162b2. Herein, we report the first case of a histologically confirmed severe myocarditis following the third dose of BNT162b2 COVID-19 vaccine.
接种针对2019冠状病毒病（COVID-19）的信使核糖核酸（mRNA）疫苗与发生心肌炎和心包炎的风险相关，根据以色列一项大型全国性研究，与基于历史数据的预期发病率相比，估计心肌炎的标准化发病率为5.34（95%置信区间，4.48至6.40）。疫苗接种者中的大多数心肌炎病例发生在年轻男性中，尤其是在接种第二剂之后，且症状通常较轻。最近，已证明第三剂（加强）疫苗即使针对该病毒的常见变种也能减少确诊感染和重症。在以色列，超过440万公民（超过45%的人口）已接种第三剂辉瑞-生物新技术公司的BNT162b2疫苗。在此，我们报告首例经组织学确诊的接种第三剂BNT162b2 COVID-19疫苗后发生的严重心肌炎病例。
